UNSPSC 51131812: Romiplostim

This classification denotes a therapeutic colony stimulating factor with the molecular formula C1317H2043N361O395S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GN5XU2DXKV, more generally known as romiplostim. European Medicines Agency schedules romiplostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27756. The term ROMIPLOSTIM is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 22, no. 1, 2008, list 59.

As of Q4 2014, ROMIPLOSTIM remains the US FDA Preferred Term for this commodity.

UNSPSC 51131812 Romiplostim is a Commodity code that classifies a specific pharmaceutical product — a thrombopoietin receptor agonist used to treat thrombocytopenia. State and local governments procure romiplostim primarily through health department pharmaceutical acquisition programs, correctional-facility medical services, and state employee health plans. The recent solicitation activity under this code, however, shows a categorical mismatch: Sourcewell, a Minnesota cooperative purchasing unit, issued RFP #061626 on May 12, 2026 for law enforcement equipment — body armor, duty gear, weapons systems, and related tactical supplies — which falls entirely outside romiplostim's pharmaceutical scope and suggests the code was applied in error or the opportunity was mistagged by the posting authority.

The single recent opportunity of record shows no pharmaceutical procurement activity aligned with romiplostim's actual therapeutic classification. Sourcewell's law enforcement equipment solicitation, due June 16, 2026, is structured as a cooperative purchasing vehicle serving Franklin County, Grant County, Grays Harbor County, Chelan County, Yakima County, and numerous other jurisdictions across the United States and Canada, with participation open to state and local agencies, higher education institutions, K-12 school districts, nonprofit organizations, and tribal governments. This code appears inactive for its intended purpose in current state and local procurement activity; no legitimate romiplostim solicitations appear in the recent-opportunity record. Vendors pursuing pharmaceutical supply relationships with state and local health systems should verify the correct UNSPSC classification before responding to opportunities, as this code's recent activity does not reflect actual pharmaceutical procurement.